Analysis of patients treated with novel therapeutic agents for atopic dermatitis

Immunological analysis of patients treated with novel therapeutic agents for atopic dermatitis - Immunological analysis of patients treated with novel therapeutic agents for atopic dermatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044388

Enrollment

Registered

2021-09-01

Start date

2021-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Dupilumab or Baricitinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who have been diagnosed with atopic dermatitis and are scheduled to receive a biologic such as dupilumab or a small molecule targeted drug such as baricitinib

Exclusion criteria

Exclusion criteria: Patients who are receiving or have received systemic steroids or cyclosporine within the past 4 weeks. Patients who are receiving or have received other biologics.

Design outcomes

Primary

Measure	Time frame
Identify surface markers of immunocompetent cells, cytokines, and chemokines that correlate with the severity of skin symptoms and hematological findings before and after treatment.	—

Countries

Japan

Contacts

Public ContactChisa Nakashima

Kindai University Hospital Department of Dermatology

chisa313@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026